3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Head & Neck
3
Gastrointestinal
3
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
24
Carboplatin
18
Bevacizumab
14
Cisplatin
12
pembrolizumab
7
fluzoparib
7
Drug Therapy
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
camrelizumab
5
apatinib
5
Topotecan
5
Specimen Handling
5
Injections
5
liposomal doxorubicin
4
lenvatinib
4
famitinib
4
Tirzepatide
4
Platinum
4
Observation
4
Gemcitabine
4
Brachytherapy
4
toripalimab
3
olaparib
3
dostarlimab
3
anlotinib
3
Watchful Waiting
3
Therapeutics
3
Surveys and Questionnaires
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
trametinib
×
Gynecologic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled